SecBot SecBot
Biotech Drug Report Generated Aug 28, 2026

CTX213

CRSP·CRISPR Therapeutics AG
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical (IND-enabling)
Time to market
Unknown, at least 3-5 years if clinical trials succeed. The drug is still preclinical with no IND filed.
Why 2/10
CTX213 is a preclinical program with no hard dated catalyst (IND filing, PDUFA, or pivotal readout) scheduled within the next ~12 months. It is one of many pipeline assets at CRISPR Therapeutics, which has an approved product (CASGEVY) and multiple Phase 1/2 programs. Per the rubric, a preclinical program with no scheduled binary catalyst and representing a small part of a larger pipeline scores 2.
Actionable Insight NEUTRAL

CTX213 is too early-stage to drive near-term CRSP stock movement. Investors should focus on CRISPR Therapeutics' nearer-term catalysts: CASGEVY commercial ramp, Phase 1/2 data for CTX310 (hypertriglyceridemia) and zugo-cel (autoimmune), and any IND filing announcement for CTX213. The diabetes program is a long-duration call option, not a near-term trading catalyst.

Price Chart

Loading chart...

Executive Summary

CTX213 is CRISPR Therapeutics' next-generation, gene-edited stem-cell therapy for Type 1 diabetes, currently in preclinical/IND-enabling development. It replaces the earlier encapsulated candidate CTX211 with a "deviceless" approach, unencapsulated hypoimmune islet cells designed to evade immune attack. While preclinical data is encouraging and the company plans to move toward clinical trials, there is no IND filed, no registered trial, and no hard catalyst on the horizon. CTX213 is a small piece of CRISPR Therapeutics' broader pipeline, which is anchored by the approved CASGEVY and several Phase 1/2 assets in cardiovascular, autoimmune, and oncology indications. For a non-medical investor, CTX213 is a long-duration, high-risk/high-reward pipeline program with no near-term binary event.

How It Works

CTX213 is a "deviceless" beta-cell replacement therapy for Type 1 diabetes. It uses CRISPR-Cas9 gene editing to turn stem cells into insulin-producing islet cells that are engineered to be "hypoimmune", invisible to the patient's immune system. Unlike the earlier version (CTX211), CTX213 is not placed inside a protective capsule; it is injected directly, relying on its gene edits to avoid immune rejection without lifelong immunosuppressive drugs.

Trial Status

CTX213 is in preclinical development with no IND filed and no clinical trial registered on ClinicalTrials.gov as of mid-2026. It has demonstrated "compelling preclinical efficacy data via direct administration" according to company filings. The predecessor candidate CTX211 (encapsulated version) had a Phase 1/2 trial that was terminated, and data from that program informed the shift to CTX213. The company is advancing CTX213 toward clinical testing and plans to initiate clinical trials.

The Two-Sided Case

▲ Bull Case4
CTX213 addresses a massive market: the global Type 1 diabetes population (~8-10 million) who currently require lifelong insulin therapy.
The 'deviceless' approach eliminates the encapsulation device, potentially simplifying manufacturing and administration vs. predecessor CTX211.
CRISPR Therapeutics has a non-exclusive IP license deal with Vertex for hypoimmune cell therapies in T1D, providing potential milestone/royalty income.
Preclinical efficacy data is described as 'compelling' by the company, and the program is being actively advanced toward the clinic.
▼ Bear Case5
CTX213 is preclinical with no IND filed, it may never enter or succeed in human trials; most preclinical drug candidates fail.
Vertex (a much larger competitor) opted out of the CRISPR diabetes collaboration in 2024 and is developing its own islet cell therapies (VX-880), creating a formidable competitive threat.
The predecessor CTX211's Phase 1/2 trial was terminated, raising questions about the underlying technology.
CTX213 is a small part of CRISPR Therapeutics' pipeline; even major success would take years to impact the stock, while the near-term value drivers are CASGEVY sales and other Phase 1/2 readouts.
No hard catalyst date exists, investors cannot trade a specific binary event in the next 12 months.

Upcoming Catalysts

  • IND filing (no specific date announced)
  • Initiation of first clinical trial (company stated plans as of Feb 2026 but no timeline given)
  • Potential preclinical data presentations at medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CRISPR Therapeutics AG PRESS-RELEASE CRSP ·Originating report

Sources · 9

Hover a chip for the title
1 crisprtx.com2 type1.science3 adisinsight.springer.com4 synapse.patsnap.com5 tipranks.com6 tradingview.com7 crisprtx.com8 ebs.publicnow.com9 fiercebiotech.com